[ Price : $8.95]
FDA expands its medical device Early Alert program to cover all products that may pose significant safety risks.[ Price : $8.95]
CDER director George Tidmarsh urges more compliance with clinical trial reporting requirements through the Clinicaltrials.gov gate...[ Price : $8.95]
AbbVie files an NDA for tavapadon, an investigational once-daily oral therapy for Parkinsons disease.[ Price : $8.95]
FDA grants Essilor a de novo marketing authorization for its Stellest eyeglass lenses, which are designed to both correct vision a...[ Price : $8.95]
FDA approves a Crinetics NDA for Palsonify (paltusotine) for treating adults with acromegaly who have had an inadequate response t...[ Price : $8.95]
FDA sends Novartis Pharmaceuticals an untitled letter citing the companys allegedly false or misleading direct-to-consumer televis...[ Price : $8.95]
Capricor Therapeutics reaches agreement with FDA on the design and role of its HOPE-3 trial as it works to resubmit its BLA for De...[ Price : $8.95]
Hansa Biopharma says imlifidase met the primary endpoint in a pivotal Phase 3 study in kidney transplant patients.